Abstract

The SPCs (subtilisin-like pro-protein convertases) are a family of enzymes responsible for the proteolytic processing of numerous precursor proteins of the constitutive and regulated secretory pathways. SPCs are themselves synthesized as inactive zymogens. Activation of SPCs occurs via the intramolecular autocatalytic removal of the prodomain. SPC prodomains have been proposed as templates in the development of potent and specific SPC inhibitors. In this study, we investigated the specificity and potency of complete prodomains and short C-terminal prodomain peptides of each SPC on highly purified, soluble enzyme preparations of human SPC1, SPC6, and SPC7. Progress curve kinetic analysis of prodomain peptides and complete prodomains showed competitive inhibitory profiles in the low nanomolar range. Complete prodomains were 5-100 times more potent than C-terminal prodomain peptides, suggesting that N-terminal determinants are involved in the recognition process. However, complete prodomains and prodomain peptides exhibit only a partial specificity toward their cognate enzyme. Ala-scan structure activity studies indicated the importance of basic residues in the P(4), P(5), and P(6) positions for inhibition of SPC1. In contrast, hydrophobic residues in P(6) and P(7), as well as basic residues in P(4) and P(5), were critical for inhibition of SPC7. Our data demonstrated that the use of prodomains as specific inhibitors acting in trans would be of limited usefulness, unless modified into more specific compounds.

Highlights

  • Proteolytic processing is a post-translational modification by which a cell diversifies and controls the protein products of its genes

  • We investigated the specificity and potency of complete prodomains and short C-terminal prodomain peptides of each SPC on highly purified, soluble enzyme preparations of human SPC1, SPC6, and SPC7

  • The SPC family of enzymes consists of seven distinct members named, using the unified nomenclature of Chan et al [3], SPC1, SPC2 (PC2), SPC3 (PC1/PC3), SPC4 (PACE4), SPC5 (PC4), SPC6 (PC5/PC6), and SPC7 (LPC/PC7/PC8)

Read more

Summary

Introduction

Proteolytic processing is a post-translational modification by which a cell diversifies and controls the protein products of its genes. SPCs are involved in many important biological processes, including zymogen activation [6, 7], peptide hormone processing (18 –21), complement activation [22], clot formation and lysis [23], angiogenesis [24], and tissue remodeling [25, 26]. These proteases have been implicated in a number of pathophysiologies, raising the possibility that SPC inhibitors may become useful therapeutic agents [1, 27,28,29]. The development of highly potent and specific SPC inhibitors requires a better knowledge of the molecular determinants of catalytic activity that distinguish each member of the SPC family

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call